327.14

3.58% 12.58

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $327.14, with a volume of 155.33K. It is up +3.58% in the last 24 hours and up +22.23% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Previous Close:

$314.56

Open:

$318.77

24h Volume:

155.33K

Relative Volume:

0.32

Market Cap:

$9.13B

Revenue:

$7.46M

Net Income/Loss:

$-326.53M

P/E Ratio:

-24.45

EPS:

-13.3803

Net Cash Flow:

$-282.53M

1W Performance:

+0.58%

1M Performance:

+22.23%

6M Performance:

+9.17%

1Y Performance:

+507.89%

1-Day Range:

$313.58

$327.75

1-Week Range:

$307.88

$343.11

52-Week Range:

$37.19

$366.52

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1095)

Industry

Biotechnology (612)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

10,998

Twitter

Next Earnings Date

2026-08-03

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	327.58	8.77B	7.46M	-326.53M	-282.53M	-13.38
VRTX Vertex Pharmaceuticals Inc	474.20	121.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	655.50	69.52B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	863.54	54.49B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	184.69	39.11B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	282.02	38.46B	4.29B	577.22M	641.34M	4.2086

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-02-26	Initiated	Wells Fargo	Equal Weight
Dec-15-25	Reiterated	Oppenheimer	Outperform
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Jul 13, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 13, 2026

PRAX Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus

Jul 13, 2026

Piper Sandler reiterates Praxis Precision Medicines stock rating - Investing.com

Jul 13, 2026

Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating - Investing.com

Jul 13, 2026

Jul 12, 2026

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits

Jul 12, 2026

Jul 11, 2026

Understanding the Setup: (PRAX) and Scalable Risk - Stock Traders Daily

Jul 11, 2026

Jul 10, 2026

Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says - Moomoo

Jul 10, 2026

Jul 09, 2026

Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus - Ad Hoc News

Jul 09, 2026

Jul 08, 2026

Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026